PharmaShots | Incisive News in 3 Shots

Subscribe Now

Biocon Biologics

Biocon Biologics’ Yesafili (biosimilar, aflibercept) Receives EC’s Approval for Ophthalmic Conditions

Biocon Biologics’ Yesafili (biosimilar, aflibercept) Receives EC’s Approval for Ophthalmic Conditions

September 22, 2023

Biocon Biologics Receives EMA’s CHMP Positive Opinion of Yesafili (biosimilar, aflibercept)

Biocon Biologics Receives EMA’s CHMP Positive Opinion of Yesafili (biosimilar, aflibercept)

July 24, 2023

Biocon Biologics and its Partner Viatris Receive the Complete Response Letter from the US FDA for Bevacizumab Biosimilar

Biocon Biologics and its Partner Viatris Receive the Complete Response Letter from the US FDA for Bevacizumab Biosimilar

January 12, 2023

PharmaShots Weekly Snapshots (April 26 - 30, 2021)

PharmaShots Weekly Snapshots (April 26 - 30, 2021)

April 30, 2021

PharmaShots Weekly Snapshots (Mar 01 - 05, 2021)

PharmaShots Weekly Snapshots (Mar 01 - 05, 2021)

March 5, 2021

PharmaShots Weekly Snapshot (February 01-05, 2021)

PharmaShots Weekly Snapshot (February 01-05, 2021)

February 5, 2021

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us